Delivery Order SPE2DB22D1202-SPE2DB25FUZK5
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order on October 28, 2025, by the Defense Logistics Agency to supply 60 tablets of Multaq 400 mg, a pharmaceutical product used in cardiac care. The contract is valued at $3,516.61 and carries a firm fixed price with an ultimate completion date of October 29, 2025. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 17, 2025, for the supply of Multaq 400 mg tablets (60-count units) with a ceiling value of $1,025.26. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 18, 2025, and performance based in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a delivery order award from the Defense Logistics Agency (DLA) on November 4, 2025, for the supply of Multaq 400 mg tablets (60-count units). This non-set-aside, competitively awarded contract carries a ceiling value of $6,452.52 and is structured as a firm fixed price delivery order with an ultimate completion date of November 5, 2025. The award will be performed at AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a $1,718.81 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 tablets of Multaq 400 mg, a pharmaceutical product used in cardiac arrhythmia management. The award, issued on August 25, 2025, with an ultimate completion date of August 26, 2025, represents a child delivery order under AmerisourceBergen's larger contract vehicle with DLA. This delivery order was competitively awarded with no set-aside designation, reflecting...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 18, 2025, for the supply of Multaq 400 mg tablets (60-count units) with a ceiling value of $39,351.89. This competitive, non-set-aside award utilizes firm fixed-price pricing and is expected to be completed by September 19, 2025. The contract is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on November 3, 2025, by the Defense Logistics Agency for the supply of MULTAQ 400 mg tablets (60-count packages) with a ceiling value of $2,847.93. This competitive, firm fixed-price delivery order, which is due for completion by November 4, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a $11,497.10 firm fixed price delivery order by the Defense Department's Medical Supply Chain on September 12, 2025, for 60 tablets of Multaq 400mg. The award was made competitively with no set-aside designation and has an ultimate completion date of October 9, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the...
- The Defense Logistics Agency awarded a delivery order valued at $6,351.04 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a small-value transaction under...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $39,232.30 by the Defense Logistics Agency (DLA) for the supply of Multaq 400 mg tablets (60-count units). This non-set-aside, competitively awarded contract employs firm fixed pricing and is scheduled for completion by July 31, 2025. The award was issued on July 30, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a continuation of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for supply of Multaq 400 mg tablets (60-count units) with a ceiling value of $5,600.41. This non-competitive, firm fixed-price delivery order was awarded on April 21, 2025, with an ultimate completion date of April 22, 2025, and represents a child order under AmerisourceBergen's larger contract vehicle with DLA. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, the company's corporate...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FUZK5Delivery Order
AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on May 6, 2025, for $5,578.34 to supply 60 tablets of Multaq 400 mg, a pharmaceutical product used in cardiovascular treatment. This is a firm fixed price, non-competitive delivery order executed against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million and extending through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with completion scheduled for May 7, 2025. This delivery order represents a routine procurement under AmerisourceBergen's comprehensive pharmaceutical supply agreement with the DLA, which supports military healthcare systems and federal medical supply chains globally. As a major pharmaceutical distributor and prime contractor for federal medical procurement, AmerisourceBergen supplies a broad range of medications, vaccines, and medical devices across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities. No set-aside designation was applied to this award, reflecting AmerisourceBergen's competitive standing as a preferred vendor for federal pharmaceutical distribution.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.6k | 5/6/25 |